<?xml version='1.0' encoding='utf-8'?>
<document id="25737032"><sentence text="Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking."><entity charOffset="33-42" id="DDI-PubMed.25737032.s1.e0" text="pazopanib" /></sentence><sentence text="Metabolism-mediated drug adverse effects (e" /><sentence text="g" /><sentence text=", drug-drug interaction, bioactivation, etc" /><sentence text=") strongly limit the utilization of clinical drugs" /><sentence text=" The present study aims to predict the metabolic capability of cytochrome P450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers especially for ovarian cancer" /><sentence text=" Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was methyl group located besides nitrogen in the five-membered ring"><entity charOffset="1-10" id="DDI-PubMed.25737032.s7.e0" text="Pazopanib" /><entity charOffset="99-108" id="DDI-PubMed.25737032.s7.e1" text="pazopanib" /><entity charOffset="113-119" id="DDI-PubMed.25737032.s7.e2" text="methyl" /><entity charOffset="142-150" id="DDI-PubMed.25737032.s7.e3" text="nitrogen" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e0" e2="DDI-PubMed.25737032.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e0" e2="DDI-PubMed.25737032.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e0" e2="DDI-PubMed.25737032.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e0" e2="DDI-PubMed.25737032.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e1" e2="DDI-PubMed.25737032.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e1" e2="DDI-PubMed.25737032.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e1" e2="DDI-PubMed.25737032.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e2" e2="DDI-PubMed.25737032.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25737032.s7.e2" e2="DDI-PubMed.25737032.s7.e3" /></sentence><sentence text=" The distance between the hydrogen atom in methyl group and active center is 3"><entity charOffset="26-34" id="DDI-PubMed.25737032.s8.e0" text="hydrogen" /><entity charOffset="43-49" id="DDI-PubMed.25737032.s8.e1" text="methyl" /><pair ddi="false" e1="DDI-PubMed.25737032.s8.e0" e2="DDI-PubMed.25737032.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25737032.s8.e0" e2="DDI-PubMed.25737032.s8.e1" /></sentence><sentence text="64 Å" /><sentence text=" The interaction amino acid is Glu374"><entity charOffset="17-27" id="DDI-PubMed.25737032.s10.e0" text="amino acid" /></sentence><sentence text=" Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential"><entity charOffset="19-28" id="DDI-PubMed.25737032.s11.e0" text="pazopanib" /><entity charOffset="33-45" id="DDI-PubMed.25737032.s11.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25737032.s11.e0" e2="DDI-PubMed.25737032.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25737032.s11.e0" e2="DDI-PubMed.25737032.s11.e1" /></sentence><sentence text=" The distance between ketoconazole and activity center (2"><entity charOffset="22-34" id="DDI-PubMed.25737032.s12.e0" text="ketoconazole" /></sentence><sentence text="10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metabolism of pazopanib"><entity charOffset="42-51" id="DDI-PubMed.25737032.s13.e0" text="pazopanib" /><entity charOffset="158-167" id="DDI-PubMed.25737032.s13.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.25737032.s13.e0" e2="DDI-PubMed.25737032.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25737032.s13.e0" e2="DDI-PubMed.25737032.s13.e1" /></sentence><sentence text=" All these data were helpful for the clinical application of pazopanib, and R&amp;D of other tinib drug candidates as new anti-tumor drugs"><entity charOffset="61-70" id="DDI-PubMed.25737032.s14.e0" text="pazopanib" /></sentence><sentence text=" " /></document>